ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET ANALYSIS

Organ Transplant Immunosuppressant Drugs Market, By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Antibodies), By Transplant Type (Kidney, Liver, Heart, Lung, Pancreas, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Organ Transplant Immunosuppressant Drugs Market: Key Developments

In November 2021, the U.S. FDA approved Takeda Pharma’s, Livtencity, or maribavir, for patients 12 years of age or older with post-transplant cytomegalovirus (CMV) infection which is subsidiaries to one of four existing drugs.
In January 2020, The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 (HR 5534) extended medicare coverage of immunosuppressive drugs for kidney transplants past the 36-month cut-off currently in place to cover the medications for the life of the patients going through transplant.
In January 2020, National Kidney Foundation (NKF) applauded the new legislation recently introduced to extend Medicare coverage of immunosuppressive drugs for kidney transplant patients which will not only save lives but save taxpayers money.

Organ Transplant Immunosuppressant Drugs Market Report Snapshots